We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · November 29, 2021

TKIs and Vascular Adverse Events in Patients With Chronic Myeloid Leukemia

The Oncologist


Additional Info

The Oncologist
Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based, Propensity Score-Matched Cohort Study
Oncologist 2021 Nov 01;26(11)974-982, MT Chen, ST Huang, CW Lin, BS Ko, WJ Chen, HH Huang, FY Hsiao

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading